Skip to main content
. 2020 Jun 23;9(6):1959. doi: 10.3390/jcm9061959

Table A2.

Subgroup analysis of the effect of prior use of drugs in COVID-19 patients with hypertension.

Progression, No. (%) Improvement/Stabilization, No. (%) p
(n = 9) (n = 20) Value
Age, median (IQR) 55 (53.0–61.0) 51.5 (48.0–55.5) 0.125
Angiotensin II receptor blocker 6 (66.7%) 10 (50.0%) 0.666
Calcium channel blocker 5 (55.6%) 11 (55.0%) >0.999
Ibuprofen 2 (22.2%) 1 (5.0%) 0.453
Beta blocker 2 (22.2%) 2 (10.0%) 0.763
Diuretic 0 (0.0%) 2 (10.0%) 0.848